drugset / Trial / NCT02142153

F901318 Single Ascending Dose Study in Healthy Male Volunteers

NCT02142153

Phase 1 Completed 40 enrolled F2G Ltd Simbec Research · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.

Timeline

Start
2014-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olorofim Small molecule 0.25 mg/kg Intravenous
Subject Olorofim Small molecule 0.75 mg/kg Intravenous
Subject Olorofim Small molecule 1.5 mg/kg Intravenous
Subject Olorofim Small molecule 5 mg/kg Intravenous